Written Question·Department of Health and Social Care·UIN 64681
Prostate Cancer: Hormone Treatments
Tabled: 2 July 2025
Answered: 9 July 2025
Question
Danny Beales
Labour — Uxbridge and South Ruislip
To ask the Secretary of State for Health and Social Care, with reference to the randomised control trial study report entitled Cost utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in newly diagnosed
Answer
Karin SmythNHS England considered abiraterone as an off-label treatment for hormone sensitive, non-metastatic prostate cancer through its clinical policy development process in 2024/25. Through this process, NHS England confirmed that there was sufficient supporting...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 64681) →